# Pharmacokinetics of TNO155 in Participants With Mild, Moderate, or Severe Hepatic Impairment Compared to Matched Healthy Participants

> **NCT05490030** · PHASE1 · WITHDRAWN · sponsor: **Novartis Pharmaceuticals**

## Conditions studied

- Hepatic Impairment

## Interventions

- **DRUG:** TNO155

## Key facts

- **NCT ID:** NCT05490030
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2025-03-06
- **Primary completion:** 2025-06-26
- **Final completion:** 2025-06-26
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Sponsor's decision
- **Last updated:** 2024-02-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05490030

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05490030, "Pharmacokinetics of TNO155 in Participants With Mild, Moderate, or Severe Hepatic Impairment Compared to Matched Healthy Participants". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05490030. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*